🫀 Cardiovascular Update: GLP-1s, AI Diagnostics, Heart Failure Breakthroughs & More
From groundbreaking therapies to AI diagnostics, this update covers some of the most impactful advancements transforming cardiovascular care today.
📌 In This Episode:
✔️ GLP-1 receptor agonists after bariatric surgery reduce cardiovascular risk by sixty-seven percent.
✔️ Daxor’s blood volume analysis redefines anemia diagnosis in heart failure patients.
✔️ AI at Stony Brook enhances early detection of artery blockages through advanced plaque analysis.
✔️ Cardiac MRI outperforms standard tests in detecting early lamin-related heart disease.
✔️ Aficamten surpasses metoprolol in improving exercise capacity in HCM patients.
✔️ Abbott’s CGM linked to significantly fewer heart-related hospitalizations in real-world use.
✔️ PCOS increases hypertension risk in women by forty to one hundred percent.
✔️ Empagliflozin improves heart and kidney outcomes in obese diabetic patients.
✔️ SONATA-HCM trial explores sotagliflozin for both obstructive and non-obstructive HCM.
✔️ UK-wide AI rollout reduces unnecessary coronary procedures and boosts diagnostic efficiency.
✔️ Older heart failure patients with overlapping conditions face increased rehospitalization and decline.
✔️ mHealth app usage cuts post-discharge heart failure risks by sixty-five percent.
📢 Stay Ahead in Cardiovascular Research!
✅ Like, share, and subscribe for weekly updates on heart disease, hypertension, heart failure, and more
#Cardiology #HeartHealth #MedicalInnovation #HeartFailure #CardiovascularCare #GLP1 #AIinMedicine #HCM #Empagliflozin #PCOS #DigitalHealth #mHealth #AbbottCGM #Sotagliflozin #ClinicalResearch #LQVentures #LucidQuest